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Barriers to better care for people with AIDS in developing
countries
Andrew S Furber, Ian J Hodgson, Alice Desclaux, David S Mukasa
WHO’s “3 by 5” initiative to increase access to antiretroviral drugs to people with AIDS in
developing countries is highly ambitious. Some of the biggest obstacles relate to delivering care
Access to good quality antiretroviral treatment has
transformed the prognosis for people with AIDS in the
developed world. Although it is feasible and desirable
to deliver antiretroviral drugs in resource poor
settings,1 w1 w2 few of the 95% of people with HIV and
AIDS who live in developing countries receive them.
The World Health Organization has launched a
programme to deliver antiretroviral drugs to three mil-
lion people with AIDS in the developing world by
2005, the “3 by 5” initiative.2 w3 We identify some of the
challenges faced by the initiative, focusing on delivery
of care.
Continuum of care
Ideally, care for people with AIDS should start with vol-
untary counselling and HIV testing. However, only 10%
of people who need testing in low and middle income
countries have access to services, and therefore most are
unaware of their serological status.w5 Care should
include psychological, social, and economic support as
well as broad based medical care incorporating
nutritional advice, prevention and treatment of oppor-
tunistic infections, and palliative care.3 w6 In many
countries, this continuum remains to be set up.
The 3 by 5 initiative considers access to antiretrovi-
ral drugs as an opportunity to improve care and
enhance prevention efforts.4 However, the focus on
antiretroviral drugs risks distracting resources and
attention from a broader model of health care. A
recent survey of palliative care for people with AIDS in
developing countries showed that services were often
inadequate.5 Pain management was especially poor.
India’s decision to rapidly provide free antiretroviral
drugs to 100 000 people with AIDS in the six states
with the highest HIV prevalence created considerable
debate, partly for this reason.6 7
Countries need to take the opportunities presented
by the WHO initiative to improve their public health
infrastructure. Care for patients who do not require
antiretroviral drugs is based on regular clinical follow
up. But this kind of care, related to a chronic disease
model, is far from the acute disease model presently
dominant in the healthcare services of developing
countries.8 Setting up this new model requires
equipment, human resources, data management, and
the use of communication tools that are both efficient
and protect confidentiality.
Stigma and discrimination
The issue of confidentiality is crucially important in
view of widespread AIDS related stigma and discrimi-
nation. According to UNAIDS, AIDS related stigma is
“the process of devaluation of people living with or
associated with HIV/AIDS.”w7 Despite more than 20
years of awareness of AIDS, the stigmatisation of peo-
ple living with HIV remains strong, albeit manifested
in more sophisticated ways.9
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WHO asserts that access to antiretroviral drugs will
rapidly reduce stigma,2 and this is true at a global level
and, to an extent, at individual level. The disappearance
of “body marks” such as slimness or Kaposi’s sarcoma
is felt as a real relief.w8 Once HIV is perceived as a
chronic but treatable condition, one of the factors that
amplify stigma—fear of contagion and inevitable
death—is lessened. However, stigma is much more than
fear of contagion. It is also a tool used by cultures to
exclude those felt to have broken extant rules. The
dominant stereotype of people living with HIV is a
stigmatising one that casts them as immoral,10 leading
to what Goffman suggests is a spoilt identity.11 In our
view, the downgrading of HIV to a manageable disease
is unlikely to change this perception of HIV as
effectively as WHO suggests.
Antiretroviral drugs may also be stigmatising.
Patients taking antiretroviral drugs in Senegal often
hide their medicines. Although most of their families
are supportive, some relatives still reject them.
Neighbourhood or professional relationships still con-
vey a danger of rejection, especially in contexts of con-
flict or competition.w9
Recent research suggests that use of testing services
and disclosure of status is constrained because of
“anticipated and actual stigma experienced by people
living with HIV.”w10 In tandem with the development of
AIDS care and support for health workers, the 3 by 5
initiative should promote training programmes for
healthcare workers on medical ethics and human
rights. Since antenatal clinics, sexual health services,
and tuberculosis treatment centres have been sug-
gested as entry points for AIDS care, it is important
that the stigmatising effect of AIDS does not deter
users of these services.12
Systems of delivery
Although the 3 by 5 initiative has already brought
some important technical advances, such as the devel-
opment of simplified treatment regimens and moni-
toring protocols,13 some issues related to the delivery of
antiretroviral drugs remain. Some experts have argued
that the best way to deliver highly active antiretroviral
drugs treatment (HAART) is likely to be through
directly observed therapy (DOT), so called DOT-
HAART,w11 in order to support adherence.
Lessons need to be learnt from the use of DOTs in
tuberculosis.14 Although most developing countries have
adopted DOTs for tuberculosis, and some have seen
apparent successes,15 not all randomised controlled trials
show that DOTs confer benefit.w12 w13 Experience in
Africa has been highly variable.16 Treatment completion
rates vary from 37% (low) in the Central African Repub-
lic to 78% (moderate) in Kenya and Tanzania. Clearly
multiple approaches to delivering antiretroviral drugs
will be required to close such gaps.
Senegal, Malawi, and South Africa have achieved
high and sustainable adherence rates for antiretroviral
drugs without directly observed treatment.17 w4 The
important factors seem to be the regular supply of
medicines, efficient health service management, and
support through “antiretroviral drugs literacy promo-
tion” and self support groups.
As the quality of life for patients on antiretroviral
drugs improves, frequent contact with healthcare pro-
viders may be difficult. In Dakar, missing monthly
appointments to obtain antiretroviral drugs was the
first reason for non-compliance among patients in
their second year of treatment.w14 Most patients had
returned to their jobs, often requiring stays far from
home, especially for sailors and retailers. A visit to the
hospital to obtain antiretroviral drugs often takes
several hours, which is inconvenient for all patients.
Community involvement
Delivering antiretroviral drugs to three million people
in developing countries by 2005 will require huge
increases in trained staff; an estimated 100 000 trained
health providers and treatment supporters will be
required by the end of 2005.w15 The initiative plans to
involve community based organisations and include
people with AIDS at all levels. Administering such a
workforce risks diverting scarce healthcare managers
from already overloaded essential programmes.
Community based organisations are very heteroge-
neous. In countries such as Burundi they have set up
whole AIDS care programmes, whereas in other coun-
tries their role is more limited, perhaps relating only to
communication of prevention messages. Healthcare
workers may find it difficult to accept such organisa-
tions as partners, especially if they have promoted tra-
ditional medicines for AIDS or faith healing.w16 w17 An
evaluation in Burkina Faso has shown that although
community based organisations are thought to be
more accessible, more supportive, and more able to
guarantee follow up than healthcare services, they have
poor results because of losing patients.w18 Internal
power distribution within the organisations may mean
that people in greatest need of treatment are not the
ones who get first access to antiretroviral drugs, and
this can result in disaffection among potential users.
Training may be insufficient to change the social strat-
egies and issues of established community organisa-
tions, healers, or groups. Defining criteria to select
possible partners will be a hard task.
Access to treatment
Concern has been voiced that existing criteria for access
are inequitable.18 Presently most programmes providing
treatment do so at different tariffs based on different
ways of considering equity. A patient who gets free treat-
ment in one programme might be asked for a payment
in excess of average monthly wages in a neighbouring
programme. Providing free or subsidised treatment on a
first come, first served basis tends to favour richer, urban,
and more educated people. Perversely, these are the
people in whom treatment might be least effective as
many of them will have previously purchased antiretro-
viral drugs through private facilities. Leaving decisions
about charges to front line staff leads to inconsistencies
and may lead to corruption.
Criteria for access to subsidised antiretroviral drugs
in national programmes differ substantially between
countries. In West Africa, these criteria are based on
social characteristics, level of income, profession, social
status, and number of dependants.w19 Perceptions of
equity differ at local levels, often related to a commu-
nity’s social dynamics. Such variation is difficult to
manage from both a public health and a clinical
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perspective and doesn’t fulfil requirements for equity at
national or international levels.
Introducing user charges is likely to be inequitable as
well as adversely affecting adherence.18 19 Many families
will already be living in poverty as a result of a reduction
in income or paying for AIDS care. Providing free access
to antiretroviral drugs based on rights and not ability to
pay,19 as occurs in the Senegal national programme, will
be most equitable, will resolve dilemmas over the
treatment of migrants, and will also reduce migration to
obtain antiretroviral drugs.
Conclusions
The 3 by 5 initiative faces important challenges in
meeting the desperate need for antiretroviral drugs in
many developing countries,. Constructive dialogue
between stakeholders with different agendas, including
healthcare workers, public health managers, commu-
nity and faith based organisations, and people with
AIDS, will be crucial if the initiative is to succeed. The
prevailing social strategies must be considered
carefully when setting up programmes and working
relationships, in order to capitalise on and not
undermine the existing social order. In an interview in
Bangkok, the executive director of UNAIDS noted that
“antiretroviral therapy is still a rare commodity, and it
will be for some time. The result of that is always higher
price, and also higher price in terms of power.Who has
access to it, and who comes first: it’s a terrible issue.”w20
Without addressing this and the other issues we have
raised, the 3 by 5 initiative may fall short of its goals.
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Natural killer cells, miscarriage, and infertility
Ashley Moffett, Lesley Regan, Peter Braude
Enthusiasm for new treatments aimed at natural killer cells in women with reproductive failure is
unfortunately not backed up by the science
Natural killer (NK) cells have an important role in the
early responses to viral infections and have also been
linked with failure of pregnancy. Recent reports in the
media and the internet have exposed women to a baf-
fling array of conflicting information about tests for
NK cells and “cures” for infertility and miscarriage.
These are based on the premise that malfunction of
NK cells causes these conditions. Increasingly, clinics
are offering blood tests to measure the number and
activity of circulating NK cells. As a result of these
investigations, many women are offered treatments
such as steroids, intravenous immunoglobulins, and
tumour necrosis factor  blocking agents. The scientific
rationale for these tests and treatments, however, is not
supported by our current knowledge of the function of
uterine NK cells.
Summary points
The 3 by 5 initiative aims to deliver antiretroviral drugs to three
million people with HIV infection in developing countries by 2005
To succeed, the initiative must develop a chronic disease model of
care through a strengthened public health infrastructure
Cooperation is needed with existing essential programmes to
manage scarce health staff
The influence of stigma requires monitoring
Access to treatment must be based on rights and not ability to pay
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